Why the study?
The prognostic value of follow-up CMR in patients with dilated cardiomyopathy was unclear.
Does mid-term cardiovascular magnetic resonance follow-up improve prognostic risk stratification compared to baseline CMR in patients with non-ischemic dilated cardiomyopathy?
Does mid-term cardiovascular magnetic resonance follow-up improve prognostic risk stratification compared to baseline CMR in patients with non-ischemic dilated cardiomyopathy?
Mid-term follow-up CMR provides superior prognostic risk stratification compared to baseline CMR in patients with non-ischemic dilated cardiomyopathy, with follow-up LVEF and native T1 serving as independent predictors of MACE.
Answers are grounded in this paper and cite their sources.
Mid-term CMR follow-up may refine MACE risk stratification in non-ischemic dilated cardiomyopathy; leaves open prospective validation before practice change.
BACKGROUND: The prognostic value of follow-up cardiovascular magnetic resonance (CMR) in dilated cardiomyopathy (DCM) patients is unclear. We aimed to investigate the prognostic value of cardiac function, structure, and tissue characteristics at mid-term CMR follow-up. METHODS: The study population was a prospectively enrolled cohort of DCM patients who underwent guideline-directed medical therapy with baseline and follow-up CMR, which included measurement of biventricular volume and ejection fraction, late gadolinium enhancement, native T1, native T2, and extracellular volume. During follow-up, major adverse cardiac events (MACE) were defined as a composite endpoint of cardiovascular death, heart transplantation, and heart-failure readmission. RESULTS: Among 235 DCM patients (median CMR interval: 15.3 months; interquartile range: 12.5-19.2 months), 54 (23.0%) experienced MACE during follow-up (median: 31.2 months; interquartile range: 20.8-50.0 months). In multivariable Cox regression, follow-up CMR models showed significantly superior predictive value than baseline CMR models. Stepwise multivariate Cox regression showed that follow-up left ventricular ejection fraction (LVEF; hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.91-0.96; p < 0.001) and native T1 (HR, 1.01; 95% CI, 1.00-1.01; p = 0.030) were independent predictors of MACE. Follow-up LVEF ≥ 40% or stable LVEF < 40% with T1 ≤ 1273 ms indicated low risk (annual event rate < 4%), while stable LVEF < 40% and T1 > 1273 ms or LVEF < 40% with deterioration indicated high risk (annual event rate > 15%). CONCLUSIONS: Follow-up CMR provided better risk stratification than baseline CMR. Improvements in the LVEF and T1 mapping are associated with a lower risk of MACE.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: